BLFS vs CYRX
BLFS: BioLife Solutions provides critical biopreservation and cold chain technologies essential for the storage and transport of high-value cell and gene therapies. CYRX: Cryoport is a specialized provider of mission-critical, temperature-controlled supply chain solutions for the fast-growing cell and gene therapy market.
Side-by-side fundamentals
| Metric | BLFS | CYRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $38.61 | $16.90 | |
| Market cap | $1.9B | $856M | |
| P/E as of 2026-10-08 | 32.67 | n/a | |
| Net margin FY2025, SEC XBRL | n/a | +44.4% | |
| Gross margin FY2025, SEC XBRL | n/a | +47.1% | |
| Operating margin FY2025, SEC XBRL | n/a | -20.9% | |
| ROE FY2025, SEC XBRL | -1.2% | +15.6% | CYRX higher |
| ROA FY2025, SEC XBRL | -1.1% | +10.2% | CYRX higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.38 | BLFS lower |
| Revenue growth (YoY) as of 2026-09-03 | +34.4% | -8.0% | BLFS higher |
| Revenue CAGR (3y) SEC XBRL | +30.9% | -9.4% | BLFS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.29 | 1.55 | |
| 1-year return as of 2026-10-08 close | +41.2% | +68.0% | CYRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.